At least 13 biotechs and pharmas are slated to report earnings this week. Specialty pharmas Allergan Inc. (NYSE:AGN) and H. Lundbeck A/S (CSE:LUN) are both expected to announce quarterly EPS growth of 19% or more compared with 4Q11. Fourth quarter revenues for Allergan are expected to increase 8% over 4Q11 to $1.5 billion. Lundbeck's top-line is anticipated to be off 1% to DKK3.8 billion ($667.4 million) due to the loss of U.S. patent exclusivity for its antidepressant Lexapro escitalopram